The Diabetes Pearl: Diabetes biobanking in The Netherlands

BMC Public Health

Jacqueline M Dekker⁵  Coen DA Stehouwer⁶  Bruce HR Wolffenbuttel⁷  Harold W de Valk³  Cees J Tack^1,10  Bianca Silvius³  Eric JG Sijbrands¹  Nicolaas C Schaper⁴  Hanno Pijl²  Behiye Özcan¹  Giel Nijpels⁹  Frits Holleman⁸  Marja W Dijk-Schaap²  Wanda M Admiraal⁸  Evertine J Abbink^1,10  Miranda T Schram⁶  Esther van’t Riet⁵ 

[1] Erasmus University Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands;Leiden University Medical Center, Department of Edocrinology & Metabolism, Leiden, The Netherlands;University Medical Center Utrecht, Department of Internal Medicine, Utrecht, The Netherlands;Maastricht University Medical Center, School for Public Health and Primary Care, Maastricht, The Netherlands;VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam, The Netherlands;Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands;University Medical Center Groningen, Department of Endocrinology, Groningen, The Netherlands;Academic Medical Center Amsterdam, Department of Internal Medicine, Amsterdam, The Netherlands;VU University Medical Center, Department of General Practice, Amsterdam, The Netherlands;Radboud University Nijmegen Medical Center, Department of Internal Medicine, Nijmegen, The Netherlands

关键词: The Netherlands;    Type 2 diabetes;    Research infrastructure;    Biobank;    Design;   

Others  :  1162880
DOI  :  10.1186/1471-2458-12-949

 received in 2012-09-27, accepted in 2012-10-22,  发布年份 2012

【 摘 要 】

Background

Type 2 diabetes is associated with considerable comorbidity and severe complications, which reduce quality of life of the patients and require high levels of healthcare. The Diabetes Pearl is a large cohort of patients diagnosed with type 2 diabetes, covering different geographical areas in the Netherlands. The aim of the study is to create a research infrastructure that will allow the study of risk factors, including biomarkers and genetic determinants for severe diabetes complications.

Methods/design

Baseline examinations began November 2009 and will continue through 2012. By the end of 2012, it is expected that 7000 patients with type 2 diabetes will be included in the Diabetes Pearl cohort. To ensure quality of the data collected, standard operation procedures were developed and used in all 8 recruitment centers. From all patients who provide informed consent, the following information is collected: personal information, medication use, physical examination (antropometry, blood pressure, electrocardiography (ECG), retina photographs, ankle-brachial index, peripheral vibration perception), self-report questionnaire (socio-economic status, lifestyle, (family) history of disease, and psychosocial well-being), laboratory measurements (glucose, A1c, lipid profile, kidney function), biobank material (storage of urine and blood samples and isolated DNA). All gathered clinical data and biobank information is uploaded to a database for storage on a national level. Biobanks are maintained locally at all recruitment centers.

Discussion

The Diabetes Pearl is large-scale cohort of type 2 diabetes patients in the Netherlands aiming to study risk factors, including biomarkers and genetic markers, for disease deterioration and the development of severe diabetes complications. As a result of the well-designed research design and the national coverage, the Diabetes Pearl data can be of great value to national and international researchers with an interest in diabetes related research.

【 授权许可】

   
2012 van't Riet et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]The String of Pearls Institutehttp://www.string-of-pearls.org webcite
• [2]International Diabetes Federation: Diabetes Atlas. 2011.
• [3]Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
• [4]Zavrelova H, Hoekstra T, Alssema M, Welschen LM, Nijpels G, Moll AC, de Vet HC, Polak BC, Dekker JM: Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system west-friesland, the Netherlands. Diabetes Care 2011, 34:867-872.
• [5]Leng GC, Fowkes FG: The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992, 45:1101-1109.
• [6]Brooks R: EuroQol: the current state of play. Health Policy 1996, 37:53-72.
• [7]Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M: Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project International Quality of Life Assessment. J Clin Epidemiol 1998, 51:1171-1178.
• [8]Snoek FJ, Pouwer F, Welch GW, Polonsky WH: Diabetes-related emotional distress in Dutch and U.S. diabetic patients: cross-cultural validity of the problem areas in diabetes scale. Diabetes Care 2000, 23:1305-1309.
• [9]Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lanteri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005, 114:29-36.
• [10]Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK: Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 1995, 38:437-444.
• [11]Chen YC, Wu JC, Haschler I, Majeed A, Chen TJ, Wetter T: Academic impact of a public electronic health database: bibliometric analysis of studies using the general practice research database. PLoS One 2011, 6:e21404.
• [12]Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA: Mortality in people with type 2 diabetes in the UK. Diabet Med 2006, 23:516-521.
• [13]Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjornsdottir S, Eliasson B: Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009, 52:65-73.
• [14]Azoulay L, Schneider-Lindner V, Dell’aniello S, Schiffrin A, Suissa S: Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case–control study. Pharmacoepidemiol Drug Saf 2010, 19:335-342.
• [15]Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, Li L: China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011, 40:1652-1666.
• [16]Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ: Prevalence and determinants of glucose intolerance in a Dutch caucasian population The Hoorn Study. Diabetes Care 1995, 18:1270-1273.